Table 1. Baseline characteristics of ten included prospective trials.

Authors/ year	Phase	Patients enrolled	Treatment Arm	Median age (y)	Median PFS (m)	Median OS (m)	No. for analysis
Kwak E.L. et al/2010 [27]	Expansion cohort	82	Crizotinib 250 mg bid po	51	NR	NR	82
Camidge D.R. et al/2012 [28]	Expansion cohort	149	Crizotinib 250 mg bid po	52	9.7	NR	149
Shaw A.T. et al/2013 [24]	III	347	Crizotinib 500 mg bid po	51	7.7	20.3	172
			Chemotherapy	49	3	22.8	171
Shaw A.T. et al/2014a [29]	Expansion cohort	81	Ceritinib 750 mg qd po	53	NR	NR	81
Shaw A.T. et al/2014b [30]	Expansion cohort	50	Crizotinib 250 mg bid po	53	19.2	NR	50
Solomon B.J. et al/2014 [25]	III	343	Crizotinib 500 mg bid po	52	10.9	NR	171
			Chemotherapy	54	7	NR	169
Shaw A.T. et al/2016 [33]	II	87	Alectinib 600 mg bid po	54	NR	NR	87
Kim D.W. et al/2016 [31]	Expansion cohort	255	Ceritinib 750 mg qd po	NR	NR	NR	255
Ou S.H. et al/2016 [32]	II	138	Alectinib 600 mg bid po	52	8.9	NR	138
Soria J.C. et al/2017 [26]	III	376	Ceritinib 750 mg qd po	55	16.6	NR	189
			Chemotherapy	54	8.1	NR	175

Abbreviations: PFS, progression-free survival; OS, overall survival; NR, not reported